Docetaxel as Second Line Therapy in Advanced Non-small Cell Lung Cancer—The Dose and Combination May Matter!
Authors:
- 1 September 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (9) , 1078-1079
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Influence of Previous Chemotherapy on the Efficacy of Subsequent Docetaxel Therapy in Advanced Non-small Cell Lung Cancer PatientsJournal of Thoracic Oncology, 2008
- A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancerLung Cancer, 2007
- Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysisJNCI: Journal of the National Cancer Institute, 2007
- Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Docetaxel for treatment of solid tumours: a systematic review of clinical dataThe Lancet Oncology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000